01 June 2022



Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

# **Decmil Group Ltd (DCG)**

## **Mining Services**

## **BUY**

## DCG A\$0.12 TARGET PRICE A\$0.24

Decmil Group Limited, through its subsidiaries, provides design, civil engineering, and construction works for the oil and gas, resources, and infrastructure sectors in Australia. The company offers various civil works, such as large and small-scale brown field and green field projects in regional and remote areas, including industrial zones and port facilities; and basic and complex works.

**Company Data** 

Company Data	
Number of shares	155.1
Market Capitalisation (\$m)	17.8
Free float (%)	98.0
12-month high/low	\$0.515/\$0.096
Average Daily Turnover (\$m)	0.000058
% S&P/ASX200	0.001%
DDM Ranking	24
% All Ordinaries	0.001%
GICS Industry Group  Source: FactSet, Barclay Pearce Capital	Industrial Services


Earnings Summary (AUD)

Laithings Summary (AOD)				
Year end June	2021A	2022F	2023F	2024F
Revenue (\$M)	313.4	437.9	527.4	607.3
EBITDA (\$M)	7.6	-14.9	14.7	21.3
Reported NPAT (\$M)	-11.5	-10.7	4.1	11.5
Adjusted NPAT (\$M)	-1.8	-10.7	4.1	11.5
Reported EPS (¢)	-8.9	-15.8	-0.6	N/A
Adjusted EPS (¢ - FD)	0.0	-6.5	2.1	6.0
Adjusted EPS growth (%)	N/A	N/A	N/A	N/A
Adjusted P/E (x)	N/A	N/A	5.5	1.9
Dividend (¢/sh)	0.0	0.0	0.3	2.1
Gross yield (%)	0.0	0.0	3.1	25.5
Net yield (%)	0.0	0.0	2.2	17.9
ROIC (%)	N/A	N/A	3.0	8.6

Source: Barclay Pearce Capital

Barclay Pearce Capital contributes all company estimates to Thomson Reuters, FactSet, Nucleus 195 and Capital IQ.

## Share price performance



## FY22 EBITDA Guidance

On 24<sup>th</sup> February 2022, Decmil Group Ltd (DCG) announced updates to its order book and affirms FY22 EBITDA guidance with the following highlights:

## **Highlights:**

- DCG wins three new contracts in Western Australia combined worth more than \$100m;
- The WA awards signify DCG's enhanced strategic progression into regional infrastructure and selective construction markets which are higher margin market segments of the broader construction sector:
- DCG also secures two new contracts in Victoria combined worth approximately \$37m;
- The Victorian awards highlight DCG's growing repeat revenue base with blue chip clients;
- Revenue and earnings from new contracts to be reflected in FY23 financial results; and
- FY22 EBITDA guidance retained, while FY22 revenue guidance revised, after Ryan Corner and Crookwell wind farm project commencements delayed into FY23.

#### **Guidance:**

- Revenue in FY22 is now expected to be in the range of \$400m to \$425m;
- DCG reiterates its FY22 EBITDA guidance of between (\$15m) and (\$10m);
- The vast majority of the revenue and earnings from the three contracts announced today will be reflected in DCG's FY23 financial results.

#### **CEO** comments:

DCG interim CEO, Vin Vassallo, said: "The South Hedland TAFE and Karratha Senior High School contracts follow our award earlier in the year to construct the new Port Hedland Community Centre, which illustrates the increasingly strong track record we are building in the construction of non-process infrastructure for the local Pilbara community. Our contract to deliver an apartment complex for highly-regarded property developer Stirling Capital has followed a lengthy Early Contractor Involvement (ECI) relationship and provides a prudent and strategic opportunity in the specialised luxury apartment construction market that also provides robust margin opportunities while utilising the construction skills that Decmil possesses. Additionally, our relationship with the Victorian Government is going from strength to strength and the works we have secured in the state stem from our inclusion in contractor panels, which is conducive to sustainable long-term growth."

# **Earnings changes**

DCG gave FY22 EBITDA guidance in the range of (\$15m) - (\$10m), which is in line with the market expectation of (\$14.9m). Hence, we do not expect any earnings revision for FY22 and for future periods.

## **Valuation**

We are initiating coverage on DCG with a 12-month target price of \$0.24 and with a BUY recommendation. The price target is underpinned by our valuation.

## Disclaimer

This Research Report has been prepared by Russell Wright ("Mr Wright") in his capacity as an Authorised Representative (AR: 422117) and is issued by Barclay Pearce Capital Management Pty Ltd (BPCM) AFSL 503261.

# Barclay Pearce Capital | Research



01 June 2022

Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

This Research is intended solely for the information of the particular person to whom it was provided by BPCM and should not be relied upon by any other person. The information in this Research does not purport to be complete nor does it contain all the information which a prospective investor may require. The information contained in this Research is general in nature and does not constitute advice nor a recommendation to deal. This Research does not constitute specific advice and does not take into account financial objectives or situation of an investor. All and any recipients of this Research acknowledge and agree that they must conduct and have conducted their own due diligence investigation and have not relied upon any representations of BPCM, its officers, employees, representatives or associates. BPCM has not independently verified the information contained in this Research.

BPCM assumes no responsibility for updating any information, views or opinions contained in this Research or for correcting any error or omission which may become apparent after the Research has been issued. BPCM does not give any warranty as to the accuracy, reliability or completeness of advice or information which is contained in this Research. Except insofar as liability under any statute cannot be excluded, BPCM and its officers, employees, representatives or associates do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this Research or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this Research or any other person. This is a private communication and was not intended for public circulation or publication or for the use of any third party. This Research must not be distributed or released in the United States. It may only be provided to persons who are outside the United States and are not, and are not acting for the account or benefit of, "US Persons" in connection with transactions that would be "offshore transactions" (as such terms are defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). Any securities mentioned in the Research have not been and will not be registered under the Securities Act or the securities laws of any state or jurisdiction of the United States, and may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws in the United States or to, or for the account or benefit of, a US Person. This Research does not, and is not intended to, constitute an offer or invitation in the United States, or in any other place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation. If you are not the intended recipient of this Research, please notify BPCM immediately and destroy all copies of this Research, whether held in electronic or printed form or otherwise.

#### **Disclosure of Interest**

The Company, its officers, employees, representatives and associates within the meaning of Chapter 7 of the Corporations Act may receive commissions and management fees from transactions involving securities referred to in this Research (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this Research. The Company does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### **Analyst Certification**

The research analyst(s) identified above individually certify that in respect of each security or issuer that the research analyst covers that: this report accurately reflects his or her personal views about any and all of the subject issuer(s) or securities; and no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by the research analyst(s) in this report. BPCM provides research services to its client. Mr Wright is General Manager of Research and has over thirty (30) years' experience in the financial services industry, particularly in financial analysis and research report writing. Mr Wright joined the BPCM team in 2021 where he has been involved in the research and publication of reports. Prior to this Mr Wright worked at a number of entities where he held Director/Head of Research and General Manager of Research positions. Mr Wright holds a Bachelor of Mathematics (Honours) from Edinburgh University and has completed the SDIA Accreditation Program (RG146) through DeakinPrime.

### **Conflicts of Interest**

BPCM does have material interests in the financial product discussed in this Research Report and it will receive benefits in relation to the publication of this Research Report. BPCM manages all Conflicts of Interest in accordance with its Conflicts of Interest Policy. Please contact us if you require any further information.

#### **Meanings of Barclay Pearce Capital Stock Ratings**

**Buy** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of 15% or more within a 12-month period. **Hold** – Describes stocks that are neither a buy nor underperform.

**Underperform** – Describes stocks that we expect to provide a total return (price appreciation plus net yield) of less than minus 10% within a 12-month period.

**NR** – The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Barclay Pearce Capital policies.

**Speculative Buy** – Describes stocks we research with a positive bias, whose company fundamentals and/or financials are being covered, but for which there is insufficient information for BPCM to assign a Buy or Underperform rating.

Free Float (float / current shares outstanding) \*100 – This float figure is the number of shares that are available to the public and is calculated by subtracting the shares held by insiders and those deemed to be stagnant shareholders. Stagnant holders include ESOP's, ESOT's, QUEST's, employee benefit trusts, founding shareholder equity stake plus senior management equity stake, corporations not actively managing money, venture capital companies and shares held by Governments.

#### **Valuation Methodology**

BPCM's methodology for assigning stock and credit ratings may include the following: market capitalisation, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of peer comparisons, market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of parts, net asset value, discounted dividend model (DDM), franking credits and return on equity (ROE) over the next 12 months.

Barclay Pearce Capital ACN 634 843 735 Sydney Office: Level 17, 115 Pitt Street, Sydney NSW 2000 Australia Tel: (61) 2 8288 6900

AFSL 503 261

Website: www.barclaypearce.com.au

# Barclay Pearce Capital | Research



01 June 2022

Russell Wright | T+02 8288 6900 | E:russell@barclaypearce.com.au

## **Barclay Pearce Capital Recommendation Proportions**

Buy	37.9%	0.0% of stocks with recommendations are Barclay Pearce clients)
Hold	22.8%	0.0% of stocks with recommendations are Barday Pearce clients)
Underperform	39.4%	0.0% of stocks with recommendations are Barday Pearce clients)

Barclay Pearce Capital ACN 634 843 735 AFSL 503 261

Sydney Office: Level 17, 115 Pitt Street, Sydney NSW 2000 Australia Tel: (61) 2 8288 6900 Website: www.barclaypearce.com.au